Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19

Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19

GlobeNewswire

March 16, 2022



SHANGHAI, China, March 16, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to...

Related Keywords

Kazakhstan ,Kyrgyzstan ,Xinjiang ,Jiangxi ,China ,Shanghai ,Iran ,Algeria ,Uzbekistan ,Beijing ,Russia ,San Francisco ,California ,United States ,Tunisia ,Guangzhou ,Guangdong ,Iraq ,Egypt ,Israel ,Turkmenistan ,Sudan ,Morocco ,Suzhou ,Jiangsu ,Saudi Arabia ,Maryland ,Libya ,Wuhan ,Hubei ,Turkey ,Tajikistan ,Chinese ,Junshi Biosciences ,Zhi Li ,Eli Lilly ,Institute Of Microbiology Chinese Academy ,Ir Team ,Laboratory Of The Ministry Science ,Central Asian Center ,Xinjiang Technical Institute Of Physics ,Vigonvita Life Sciences Co Ltd ,Pr Team ,Development Of Chinese Academy Sciences China ,Wuhan Institute Of Virology ,Shanghai Junshi Biosciences Co Ltd ,Junshi Biosciences Announces First Patient Dosed ,Chinese Academy ,Shanghai Institute ,Materia Medica ,Wuhan Institute ,Xinjiang Technical Institute ,Drug Discovery ,China Uzbekistan Medicine Technical Park ,Road Joint Laboratory ,Central Asian ,North Africa ,Middle East ,Emergency Use Authorizations ,